Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.45 |
| ▸ | POLG | P54098 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763169 | 1.00 | POLB (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL5362873 | 0.89 | POLB (0.49) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL5362913 | 0.89 | POLB (0.49) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL5181724 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL10431788 | 0.88 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL10432426 | 0.88 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL16359951 | 0.88 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL4579454 | 0.86 | LMNA (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL4579459 | 0.86 | LMNA (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL24533722 | 0.86 | POLB (0.55) | POLBLMNAPDE3ACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283094-A1 | Modified Nucleosides | SOMALOGIC OPERATING CO., INC. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4323374-A1 | MODIFIED NUCLEOSIDES | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221241-A1 | MODIFIED NUCLEOSIDES | SOMALOGIC OPERATING CO., INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-8614312-B2 | Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-24 | — | — | US | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-2265624-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | Centre National de la Recherche Scientifique (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115694-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-09-24 | — | — | WO | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| WO-1992020816-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283094-A1 | Modified Nucleosides | NT5C3B, PNP, TYMP | POLB 212/4885LMNA 1230/4885PDE3A 1392/4885 |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | POLB 209/4885LMNA 625/4885PDE3A 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.